September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Topical Interferon Alpha-2b In Giant Squamous Ocular Surface Neoplasia
Author Affiliations & Notes
  • Erick Hernandez-Bogantes
    Cornea and Refractive Surgery, Insituto de Oftalmologia Fundacion Conde de Valenciana, Mexico D.F, Mexico
  • Andrew Olivo-Payne
    Cornea and Refractive Surgery, Insituto de Oftalmologia Fundacion Conde de Valenciana, Mexico D.F, Mexico
  • Alexandra Abdala
    Cornea and Refractive Surgery, Insituto de Oftalmologia Fundacion Conde de Valenciana, Mexico D.F, Mexico
  • Juan Carlos Serna-Ojeda
    Cornea and Refractive Surgery, Insituto de Oftalmologia Fundacion Conde de Valenciana, Mexico D.F, Mexico
  • Enrique O Graue-Hernandez
    Cornea and Refractive Surgery, Insituto de Oftalmologia Fundacion Conde de Valenciana, Mexico D.F, Mexico
  • Alejandro Navas
    Cornea and Refractive Surgery, Insituto de Oftalmologia Fundacion Conde de Valenciana, Mexico D.F, Mexico
  • Arturo J Ramirez-Miranda
    Cornea and Refractive Surgery, Insituto de Oftalmologia Fundacion Conde de Valenciana, Mexico D.F, Mexico
  • Footnotes
    Commercial Relationships   Erick Hernandez-Bogantes, None; Andrew Olivo-Payne, None; Alexandra Abdala, None; Juan Carlos Serna-Ojeda, None; Enrique Graue-Hernandez, None; Alejandro Navas, None; Arturo Ramirez-Miranda, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3895. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Erick Hernandez-Bogantes, Andrew Olivo-Payne, Alexandra Abdala, Juan Carlos Serna-Ojeda, Enrique O Graue-Hernandez, Alejandro Navas, Arturo J Ramirez-Miranda; Topical Interferon Alpha-2b In Giant Squamous Ocular Surface Neoplasia. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3895.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To report a case series of 8 patients clinically diagnosed with giant ocular squamous neoplasia (OSSN) who underwent medical therapy with topical interferon alpha-2b for immunoreduction and immutherapy purposes

Methods : Patients received monthly dosis of topical interferon alpha-2b (1 million IU/mL) for a total of 3 months or with a subconjunctival injection (3 million IU/mL) single dose per week monthly until tumor resolution.

Results :
A total of eight eyes of 8 patients (mean age of 69 y/o) with a clinical diagnosis of unilateral giant OSSN were managed with interferon alpha-2b. Six patients received topical therapy (1 million IU/mL) 4 times per day for a minimum of 3 months for immunotherapeutic purposes and 2 patients received subconjunctival therapy (3 million IU/mL) single dose per week for 1 month for immunoreduction. The median time to resolution was 5 months (range, 1.5-6 months) and the median follow-up was 22 months (range, 6-28 months). Despite the dramatic clinical response, all patients continued with topical interferon alpha-2b at least 1 month beyond complete clinical resolution. The two cases in which immunoreduction was successfully achieved, were scheduled for a lesion excision with a no-touch technique followed by cryotherapy and amniotic membrane to cover the large excision area. There has been no recurrence during follow-up.

Conclusions : In cases of giant OSSN interferon alpha-2b can successfully reduce or achieve complete resolution, thus avoiding the patient a more extensive surgical procedure with its known risks and complications.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×